Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved the PD-L1 (SP142) Assay developed by Roche subsidiary Ventana as a complementary diagnostic for Genentech's PD-L1 inhibitor Tecentriq, which was recently approved to treat lung cancer.

The complementary assay, while not required for the safe and effective use of Tecentriq, can determine patients' PD-L1 expression levels, which in turn "can provide insight into the survival benefit that may be achieved" with treatment, Roche said in a statement today. The test gauges PD-L1 expression in tumor and immune cells.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

The New York Times Magazine examines gender discrimination at the Salk Institute.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

Apr
24
Sponsored by
Biocrates

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
07
Sponsored by
Agilent

This webinar will discuss the implementation of an enterprise-wide clinical genomics platform that is shared across 10 hospitals and research organizations in the Australian State of Victoria.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.